ESPR — Esperion Therapeutics Inc · rev $403.1M

Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.

Latest reported ESPR revenue for 2025-12-31 was $403.1M. Net income was -$22.7M. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. ESPR currently screens at market cap $816.9M.

Use this ESPR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ESPR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ESPR SEC filings page. Lician reads the product cache first so this HTML stays unique to Esperion Therapeutics Inc even when a live quote feed is slow.

Esperion Therapeutics Inc latest statements (FY2025)

Latest cached year on this hub. Full ESPR income, balance, and cash tables.

  • Revenue$403.1M
  • Net Income-$22.7M
  • Total Assets$465.9M
  • Total Debt$0
  • Free Cash Flow$0

ESPR recent filings